Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCTA01 + SCTA01C
- Development stage
- Unknown
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SCTA01 + SCTA01C is a combination of two monoclonal antibodies under investigation for the treatment and prophylaxis of COVID-19. SCTA01 (code name HB27) is a human IgG1 monoclonal antibody with an Fc LALA mutation to reduce antibody-dependent enhancement and cytotoxicity, targeting the spike protein of SARS-CoV-2 and demonstrating potent neutralizing activity in vitro and in animal models. SCTA01C is presumed to be a companion monoclonal antibody, likely targeting a different site on the viral spike protein, intended to provide synergistic or complementary neutralization in the cocktail. The combination aims to enhance efficacy against viral escape and antibody resistance. The developer is SinoCellTech, a biotechnology company in China. SCTA01 alone has demonstrated good safety and tolerability in healthy adults in a phase I clinical trial with linear pharmacokinetics, and SCTA01 + SCTA01C is being developed for similar COVID-19 indications.
- Other names
- HB27HB-27HB 27
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on SCTA01 + SCTA01C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCTA01 + SCTA01C.